A significant study discovering the market avenues on, “Precision Oncology Therapies Market Size, Share & Trends Analysis Report by Therapy Type (Targeted Therapy, Immunotherapy, Hormone Therapy, Gene Therapy, Epigenetic Therapy, Others), Cancer Type, Biomarker Type, Technology Platform, Drug Class, Route of Administration, Molecule Type, Patient Demographics, End-Users and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2026–2035” A holistic view of the market pathways in the precision oncology therapies market underscores revenue acceleration through three key levers scalable product line extensions, high‑maturity strategic partnerships
Global Precision Oncology Therapies Market Forecast 2035:
According to the report, the global precision oncology therapies market is projected to expand from USD 82.4 billion in 2025 to USD 157.6 billion by 2035, registering a CAGR of 6.7%, the highest during the forecast period. The global precision oncology therapies market is growing at remarkable rates due to the development of genomics, molecular diagnostics and targeted therapies that allow developing treatment of cancer personally. Precision oncology is a field that aims to determine individual genetic mutations and biomarkers in tumors to personalize treatment to enhance its efficacy and reduce the side effects associated with the therapies as compared to traditional methods. The major categories are targeted therapies, immunotherapies and combination therapies, where targeted therapies are the most prominent because of their already proven use in clinical practice.
Next-generation sequencing (NGS), artificial intelligence, bioinformatics and high throughput molecular profiling are all technological advances that are speeding up the identification of actionable mutations, patient stratification and therapy development. Increased government, research, and commercialization of new treatments through increased investments by governments, research institutions and individual organizations assist in continued research and clinical trials of new treatments.
Moreover, the alliances between biotech and pharmaceutical firms contribute to the promotion of innovation and access to the newest methods of treatment. The tendency toward increased cancer rates, the increased awareness of the personalized medicine, and the improvement of diagnostic methods all encourage the booming growth of the precision oncology therapies market.
“Key Driver, Restraint, and Growth Opportunity Shaping the Global Precision Oncology Therapies Market”
The discovery and commercialization of new precision cancer therapies are driven by ongoing investments in research and development, as well as a large volume of clinical studies. This expedites the delivery of biomarker-based interventions in the treatment of different types of cancer that improves patient outcomes. As an example, AbbVie has been active in pipeline development with several clinical trials of its antibody-drug conjugate, telisotuzumab adozutecan, in hard-to-treat solid tumors in 2025.
Stringent regulatory approvals, guidelines differences between regions and strict clinical validation criteria slow down the development and commercialization of biomarker-based therapies and companion diagnostics. Such complexities may slow entry into the market, drive up the cost of development, and restrict access of innovative precision oncology treatments to patients in a timely manner, thus restricting the growth of the market.
Rapid advances in artificial intelligence (AI), bioinformatics, and molecular diagnostics create significant prospects for the niche precision cancer therapies market. With the adoption of AI-based analytics and machine learning, it is now possible to integrate large amounts of genomic, clinical, and real-world data to determine the actionable mutations, forecast patient response, and optimize treatment plans. The advanced molecular diagnostics such as next-generation sequencing (NGS), and liquid biopsy systems can be used to enable early-state diagnosis, dynamic observing, and the selection of optimal therapy. The technologies improve and speed up drug development, simplify clinical trials, and enhance accuracy in treatment delivery. As an example, In May 2025, Danaher collaborated with AstraZeneca to develop AI-powered diagnostics and precision medicine solutions to develop molecular testing and target therapy in cancer.
Expansion of Global Precision Oncology Therapies Market
“Innovation, and public funding propel the global precision oncology therapies market expansion”
- The precision oncology therapies market is rapidly expanding with the influence of technological advances in artificial intelligence, bioinformatics, molecular diagnostics, and targeted drug development that allow an increase in the accuracy of biomarker identification, individual strategies, and accelerate the process of therapy development. As an example, in 2025 Roche was granted FDA Breakthrough Device Designation of its first AI-based companion diagnostic of non-small cell lung cancer (NSCLC). It is a device that uses a combination of immunohistochemistry (IHC) and an artificial intelligence algorithm to quantify TROP2 protein levels with sufficient accuracy, allowing selection of patients to receive specific targeted treatment and aid in planning regarding the suitable treatment.
- The oncology therapies market is becoming more precise because of government incentives and money can be invested privately to help in research and development, speed up clinical trials, and allow more targeted and biomarker-driven cancer therapies to be commercialized faster. As an example, the Australian Government allocated AUD 112.6 million in 2025 to extend the ZERO Childhood Cancer Program, so that genomic-based precision medicine is accessible to all children (0-18 years) and young adults (19-25 years) with pediatric-type cancers in Australia, which will allow the provision of personalized treatment plans and enhance survival rates.
Regional Analysis of Global Precision Oncology Therapies Market
- North America controls the precision oncology therapies market, because of its developed infrastructure in healthcare system, the extensive use of next-generation sequencing (NGS) and molecular diagnostics, extensive government and unicellular investments in the area of precision medicine, strong R and D, and the presence of large biopharmaceutical firms. These are enabling focused therapies to develop fast, get approved, and commercialized, leading to high market growth in the region.
- The Asia Pacific precision oncology therapies market is the most rapidly growing market because of the rising cancer incidences, rising access to healthcare, rising awareness of personalized medicine, rising use of biomarker-directed therapies and enabling regional government policies. Also, the local biotech companies and the international pharmaceutical companies are entering into joint ventures, leading to the further penetration of advanced forms of targeted therapies and rapid market growth in the emerging markets in the region.
Prominent players operating in the global precision oncology therapies market are AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, Exact Sciences Corporation, Gilead Sciences, Inc., GlaxoSmithKline plc, Incyte Corporation, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holdings AG, Sanofi S.A., Seagen Inc., Takeda Pharmaceutical Company Limited, and Other Key Players.
The global Precision Oncology Therapies Market has been segmented as follows:
Global Precision Oncology Therapies Market Analysis, By Therapy Type
- Targeted Therapy
- Small Molecule Inhibitors
- Monoclonal Antibodies
- Antibody-Drug Conjugates
- Others
- Immunotherapy
- Checkpoint Inhibitors
- CAR-T Cell Therapy
- Cancer Vaccines
- Cytokine Therapy
- Others
- Hormone Therapy
- Gene Therapy
- Epigenetic Therapy
- Others
Global Precision Oncology Therapies Market Analysis, By Cancer Type
- Lung Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
- Breast Cancer
- HER2-Positive
- Triple-Negative
- Hormone Receptor-Positive
- Colorectal Cancer
- Melanoma
- Leukemia
- Acute Myeloid Leukemia (AML)
- Chronic Lymphocytic Leukemia (CLL)
- Lymphoma
- Prostate Cancer
- Ovarian Cancer
- Gastric Cancer
- Pancreatic Cancer
- Others
Global Precision Oncology Therapies Market Analysis, By Biomarker Type
- Genetic Biomarkers
- EGFR Mutations
- PD-L1 Expression
- HER2 Overexpression
- Others
- Protein Biomarkers
- Epigenetic Biomarkers
Global Precision Oncology Therapies Market Analysis, By Technology Platform
- Next-Generation Sequencing (NGS)
- Whole Genome Sequencing
- Whole Exome Sequencing
- Targeted Gene Panels
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- In Situ Hybridization (ISH)
- FISH (Fluorescence In Situ Hybridization)
- CISH (Chromogenic In Situ Hybridization)
- Liquid Biopsy
- Microarray Technology
Global Precision Oncology Therapies Market Analysis, By Drug Class
- Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Serine/Threonine Kinase Inhibitors
- PARP Inhibitors
- mTOR Inhibitors
- CDK Inhibitors
- Proteasome Inhibitors
- Angiogenesis Inhibitors
- Immune Checkpoint Inhibitors
- Others
Global Precision Oncology Therapies Market Analysis, By Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Intramuscular
Global Precision Oncology Therapies Market Analysis, By Molecule Type
- Biologics
- Monoclonal Antibodies
- Biosimilars
- Small Molecules
- Cell & Gene Therapies
Global Precision Oncology Therapies Market Analysis, By Patient Demographics
- Pediatric Population
- Adult Population
- Geriatric Population
Global Precision Oncology Therapies Market Analysis, By End-Users
- Hospitals & Cancer Centers
- Diagnostic Laboratories
- Research & Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Ambulatory Surgical Centers
- Home Healthcare Providers
- Others
Global Precision Oncology Therapies Market Analysis, By Region
About Us
MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.
We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.
Contact Us
USA Address:
800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.
+1(302)303-2617
info@marketgenics.co
India Address:
3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.
sales@marketgenics.co
Table of Contents
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Sources
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Sources
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. Global Precision Oncology Therapies Market Outlook
- 2.1.1. Precision Oncology Therapies Market Size (Value - US$ Bn), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End-use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2026-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 2.1. Global Precision Oncology Therapies Market Outlook
- 3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.4. Trade Analysis
- 3.4.1. Import & Export Analysis, 2025
- 3.4.2. Top Importing Countries
- 3.4.3. Top Exporting Countries
- 3.5. Trump Tariff Impact Analysis
- 3.5.1. Manufacturer
- 3.5.1.1. Based on the component & Raw material
- 3.5.2. Supply Chain
- 3.5.3. End Consumer
- 3.5.1. Manufacturer
- 3.6. Raw Material Analysis
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. Rising cancer incidence and demand for personalized, targeted treatments
- 4.1.1.2. Advances in genomic profiling, biomarker discovery and companion diagnostics
- 4.1.1.3. Growth in targeted drug development and immuno-oncology with strong industry investment and collaborations
- 4.1.2. Restraints
- 4.1.2.1. High cost of therapies and associated diagnostics limiting patient access
- 4.1.2.2. Complex regulatory pathways, reimbursement challenges and small biomarker-defined patient populations
- 4.1.1. Drivers
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Ecosystem Analysis
- 4.5. Porter’s Five Forces Analysis
- 4.6. PESTEL Analysis
- 4.7. Global Precision Oncology Therapies Market Demand
- 4.7.1. Historical Market Size –Value (US$ Bn), 2020-2024
- 4.7.2. Current and Future Market Size –Value (US$ Bn), 2026–2035
- 4.7.2.1. Y-o-Y Growth Trends
- 4.7.2.2. Absolute $ Opportunity Assessment
- 4.1. Market Dynamics
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 5.1. Competition structure
- 6. Global Precision Oncology Therapies Market Analysis, By Therapy Type
- 6.1. Key Segment Analysis
- 6.2. Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, By Therapy Type, 2021-2035
- 6.2.1. Targeted Therapy
- 6.2.1.1. Small Molecule Inhibitors
- 6.2.1.2. Monoclonal Antibodies
- 6.2.1.3. Antibody-Drug Conjugates
- 6.2.1.4. Others
- 6.2.2. Immunotherapy
- 6.2.2.1. Checkpoint Inhibitors
- 6.2.2.2. CAR-T Cell Therapy
- 6.2.2.3. Cancer Vaccines
- 6.2.2.4. Cytokine Therapy
- 6.2.2.5. Others
- 6.2.3. Hormone Therapy
- 6.2.4. Gene Therapy
- 6.2.5. Epigenetic Therapy
- 6.2.6. Others
- 6.2.1. Targeted Therapy
- 7. Global Precision Oncology Therapies Market Analysis, By Cancer Type
- 7.1. Key Segment Analysis
- 7.2. Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, By Cancer Type, 2021-2035
- 7.2.1. Lung Cancer
- 7.2.1.1. Non-Small Cell Lung Cancer (NSCLC)
- 7.2.1.2. Small Cell Lung Cancer (SCLC)
- 7.2.2. Breast Cancer
- 7.2.2.1. HER2-Positive
- 7.2.2.2. Triple-Negative
- 7.2.2.3. Hormone Receptor-Positive
- 7.2.3. Colorectal Cancer
- 7.2.4. Melanoma
- 7.2.5. Leukemia
- 7.2.5.1. Acute Myeloid Leukemia (AML)
- 7.2.5.2. Chronic Lymphocytic Leukemia (CLL)
- 7.2.6. Lymphoma
- 7.2.7. Prostate Cancer
- 7.2.8. Ovarian Cancer
- 7.2.9. Gastric Cancer
- 7.2.10. Pancreatic Cancer
- 7.2.11. Others
- 7.2.1. Lung Cancer
- 8. Global Precision Oncology Therapies Market Analysis,By Biomarker Type
- 8.1. Key Segment Analysis
- 8.2. Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, By Biomarker Type, 2021-2035
- 8.2.1. Genetic Biomarkers
- 8.2.1.1. EGFR Mutations
- 8.2.1.2. PD-L1 Expression
- 8.2.1.3. HER2 Overexpression
- 8.2.1.4. Others
- 8.2.2. Protein Biomarkers
- 8.2.3. Epigenetic Biomarkers
- 8.2.1. Genetic Biomarkers
- 9. Global Precision Oncology Therapies Market Analysis, By Technology Platform
- 9.1. Key Segment Analysis
- 9.2. Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, By Technology Platform, 2021-2035
- 9.2.1. Next-Generation Sequencing (NGS)
- 9.2.1.1. Whole Genome Sequencing
- 9.2.1.2. Whole Exome Sequencing
- 9.2.1.3. Targeted Gene Panels
- 9.2.2. Polymerase Chain Reaction (PCR)
- 9.2.3. Immunohistochemistry (IHC)
- 9.2.4. In Situ Hybridization (ISH)
- 9.2.4.1. FISH (Fluorescence In Situ Hybridization)
- 9.2.4.2. CISH (Chromogenic In Situ Hybridization)
- 9.2.5. Liquid Biopsy
- 9.2.6. Microarray Technology
- 9.2.1. Next-Generation Sequencing (NGS)
- 10. Global Precision Oncology Therapies Market Analysis, By Drug Class
- 10.1. Key Segment Analysis
- 10.2. Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, By Drug Class, 2021-2035
- 10.2.1. Kinase Inhibitors
- 10.2.1.1. Tyrosine Kinase Inhibitors
- 10.2.1.2. Serine/Threonine Kinase Inhibitors
- 10.2.2. PARP Inhibitors
- 10.2.3. mTOR Inhibitors
- 10.2.4. CDK Inhibitors
- 10.2.5. Proteasome Inhibitors
- 10.2.6. Angiogenesis Inhibitors
- 10.2.7. Immune Checkpoint Inhibitors
- 10.2.8. Others
- 10.2.1. Kinase Inhibitors
- 11. Global Precision Oncology Therapies Market Analysis, By Route of Administration
- 11.1. Key Segment Analysis
- 11.2. Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, By Route of Administration, 2021-2035
- 11.2.1. Oral
- 11.2.2. Intravenous
- 11.2.3. Subcutaneous
- 11.2.4. Intramuscular
- 12. Global Precision Oncology Therapies Market Analysis, By Molecule Type
- 12.1. Key Segment Analysis
- 12.2. Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, By Molecule Type, 2021-2035
- 12.2.1. Biologics
- 12.2.2. Monoclonal Antibodies
- 12.2.3. Biosimilars
- 12.2.4. Small Molecules
- 12.2.5. Cell & Gene Therapies
- 13. Global Precision Oncology Therapies Market Analysis, By Patient Demographics
- 13.1. Key Segment Analysis
- 13.2. Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, By Patient Demographics, 2021-2035
- 13.2.1. Pediatric Population
- 13.2.2. Adult Population
- 13.2.3. Geriatric Population
- 14. Global Precision Oncology Therapies Market Analysis and Forecasts, by End-Users
- 14.1. Key Findings
- 14.2. Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, by End-Users, 2021-2035
- 14.2.1. Hospitals & Cancer Centers
- 14.2.2. Diagnostic Laboratories
- 14.2.3. Research & Academic Institutes
- 14.2.4. Pharmaceutical & Biotechnology Companies
- 14.2.5. Ambulatory Surgical Centers
- 14.2.6. Home Healthcare Providers
- 14.2.7. Others
- 15. Global Precision Oncology Therapies Market Analysis and Forecasts, by Region
- 15.1. Key Findings
- 15.2. Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
- 15.2.1. North America
- 15.2.2. Europe
- 15.2.3. Asia Pacific
- 15.2.4. Middle East
- 15.2.5. Africa
- 15.2.6. South America
- 16. North America Precision Oncology Therapies Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. North America Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 16.3.1. Therapy Type
- 16.3.2. Cancer Type
- 16.3.3. Biomarker Type
- 16.3.4. Technology Platform
- 16.3.5. Drug Class
- 16.3.6. Route of Administration
- 16.3.7. Molecule Type
- 16.3.8. Patient Demographics
- 16.3.9. End-Users
- 16.3.10. Country
- 16.3.10.1. USA
- 16.3.10.2. Canada
- 16.3.10.3. Mexico
- 16.4. USA Precision Oncology Therapies Market
- 16.4.1. Country Segmental Analysis
- 16.4.2. Therapy Type
- 16.4.3. Cancer Type
- 16.4.4. Biomarker Type
- 16.4.5. Technology Platform
- 16.4.6. Drug Class
- 16.4.7. Route of Administration
- 16.4.8. Molecule Type
- 16.4.9. Patient Demographics
- 16.4.10. End-Users
- 16.5. Canada Precision Oncology Therapies Market
- 16.5.1. Country Segmental Analysis
- 16.5.2. Therapy Type
- 16.5.3. Cancer Type
- 16.5.4. Biomarker Type
- 16.5.5. Technology Platform
- 16.5.6. Drug Class
- 16.5.7. Route of Administration
- 16.5.8. Molecule Type
- 16.5.9. Patient Demographics
- 16.5.10. End-Users
- 16.6. Mexico Precision Oncology Therapies Market
- 16.6.1. Country Segmental Analysis
- 16.6.2. Therapy Type
- 16.6.3. Cancer Type
- 16.6.4. Biomarker Type
- 16.6.5. Technology Platform
- 16.6.6. Drug Class
- 16.6.7. Route of Administration
- 16.6.8. Molecule Type
- 16.6.9. Patient Demographics
- 16.6.10. End-Users
- 17. Europe Precision Oncology Therapies Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Europe Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 17.3.1. Therapy Type
- 17.3.2. Cancer Type
- 17.3.3. Biomarker Type
- 17.3.4. Technology Platform
- 17.3.5. Drug Class
- 17.3.6. Route of Administration
- 17.3.7. Molecule Type
- 17.3.8. Patient Demographics
- 17.3.9. End-Users
- 17.3.10. Country
- 17.3.10.1. Germany
- 17.3.10.2. United Kingdom
- 17.3.10.3. France
- 17.3.10.4. Italy
- 17.3.10.5. Spain
- 17.3.10.6. Netherlands
- 17.3.10.7. Nordic Countries
- 17.3.10.8. Poland
- 17.3.10.9. Russia & CIS
- 17.3.10.10. Rest of Europe
- 17.4. Germany Precision Oncology Therapies Market
- 17.4.1. Country Segmental Analysis
- 17.4.2. Therapy Type
- 17.4.3. Cancer Type
- 17.4.4. Biomarker Type
- 17.4.5. Technology Platform
- 17.4.6. Drug Class
- 17.4.7. Route of Administration
- 17.4.8. Molecule Type
- 17.4.9. Patient Demographics
- 17.4.10. End-Users
- 17.5. United Kingdom Precision Oncology Therapies Market
- 17.5.1. Country Segmental Analysis
- 17.5.2. Therapy Type
- 17.5.3. Cancer Type
- 17.5.4. Biomarker Type
- 17.5.5. Technology Platform
- 17.5.6. Drug Class
- 17.5.7. Route of Administration
- 17.5.8. Molecule Type
- 17.5.9. Patient Demographics
- 17.5.10. End-Users
- 17.6. France Precision Oncology Therapies Market
- 17.6.1. Country Segmental Analysis
- 17.6.2. Therapy Type
- 17.6.3. Cancer Type
- 17.6.4. Biomarker Type
- 17.6.5. Technology Platform
- 17.6.6. Drug Class
- 17.6.7. Route of Administration
- 17.6.8. Molecule Type
- 17.6.9. Patient Demographics
- 17.6.10. End-Users
- 17.7. Italy Precision Oncology Therapies Market
- 17.7.1. Country Segmental Analysis
- 17.7.2. Therapy Type
- 17.7.3. Cancer Type
- 17.7.4. Biomarker Type
- 17.7.5. Technology Platform
- 17.7.6. Drug Class
- 17.7.7. Route of Administration
- 17.7.8. Molecule Type
- 17.7.9. Patient Demographics
- 17.7.10. End-Users
- 17.8. Spain Precision Oncology Therapies Market
- 17.8.1. Country Segmental Analysis
- 17.8.2. Therapy Type
- 17.8.3. Cancer Type
- 17.8.4. Biomarker Type
- 17.8.5. Technology Platform
- 17.8.6. Drug Class
- 17.8.7. Route of Administration
- 17.8.8. Molecule Type
- 17.8.9. Patient Demographics
- 17.8.10. End-Users
- 17.9. Netherlands Precision Oncology Therapies Market
- 17.9.1. Country Segmental Analysis
- 17.9.2. Therapy Type
- 17.9.3. Cancer Type
- 17.9.4. Biomarker Type
- 17.9.5. Technology Platform
- 17.9.6. Drug Class
- 17.9.7. Route of Administration
- 17.9.8. Molecule Type
- 17.9.9. Patient Demographics
- 17.9.10. End-Users
- 17.10. Nordic Countries Precision Oncology Therapies Market
- 17.10.1. Country Segmental Analysis
- 17.10.2. Therapy Type
- 17.10.3. Cancer Type
- 17.10.4. Biomarker Type
- 17.10.5. Technology Platform
- 17.10.6. Drug Class
- 17.10.7. Route of Administration
- 17.10.8. Molecule Type
- 17.10.9. Patient Demographics
- 17.10.10. End-Users
- 17.11. Poland Precision Oncology Therapies Market
- 17.11.1. Country Segmental Analysis
- 17.11.2. Therapy Type
- 17.11.3. Cancer Type
- 17.11.4. Biomarker Type
- 17.11.5. Technology Platform
- 17.11.6. Drug Class
- 17.11.7. Route of Administration
- 17.11.8. Molecule Type
- 17.11.9. Patient Demographics
- 17.11.10. End-Users
- 17.12. Russia & CIS Precision Oncology Therapies Market
- 17.12.1. Country Segmental Analysis
- 17.12.2. Therapy Type
- 17.12.3. Cancer Type
- 17.12.4. Biomarker Type
- 17.12.5. Technology Platform
- 17.12.6. Drug Class
- 17.12.7. Route of Administration
- 17.12.8. Molecule Type
- 17.12.9. Patient Demographics
- 17.12.10. End-Users
- 17.13. Rest of Europe Precision Oncology Therapies Market
- 17.13.1. Country Segmental Analysis
- 17.13.2. Therapy Type
- 17.13.3. Cancer Type
- 17.13.4. Biomarker Type
- 17.13.5. Technology Platform
- 17.13.6. Drug Class
- 17.13.7. Route of Administration
- 17.13.8. Molecule Type
- 17.13.9. Patient Demographics
- 17.13.10. End-Users
- 18. Asia Pacific Precision Oncology Therapies Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Asia Pacific Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 18.3.1. Therapy Type
- 18.3.2. Cancer Type
- 18.3.3. Biomarker Type
- 18.3.4. Technology Platform
- 18.3.5. Drug Class
- 18.3.6. Route of Administration
- 18.3.7. Molecule Type
- 18.3.8. Patient Demographics
- 18.3.9. End-Users
- 18.3.10. Country
- 18.3.10.1. China
- 18.3.10.2. India
- 18.3.10.3. Japan
- 18.3.10.4. South Korea
- 18.3.10.5. Australia and New Zealand
- 18.3.10.6. Indonesia
- 18.3.10.7. Malaysia
- 18.3.10.8. Thailand
- 18.3.10.9. Vietnam
- 18.3.10.10. Rest of Asia Pacific
- 18.4. China Precision Oncology Therapies Market
- 18.4.1. Country Segmental Analysis
- 18.4.2. Therapy Type
- 18.4.3. Cancer Type
- 18.4.4. Biomarker Type
- 18.4.5. Technology Platform
- 18.4.6. Drug Class
- 18.4.7. Route of Administration
- 18.4.8. Molecule Type
- 18.4.9. Patient Demographics
- 18.4.10. End-Users
- 18.5. India Precision Oncology Therapies Market
- 18.5.1. Country Segmental Analysis
- 18.5.2. Therapy Type
- 18.5.3. Cancer Type
- 18.5.4. Biomarker Type
- 18.5.5. Technology Platform
- 18.5.6. Drug Class
- 18.5.7. Route of Administration
- 18.5.8. Molecule Type
- 18.5.9. Patient Demographics
- 18.5.10. End-Users
- 18.6. Japan Precision Oncology Therapies Market
- 18.6.1. Country Segmental Analysis
- 18.6.2. Therapy Type
- 18.6.3. Cancer Type
- 18.6.4. Biomarker Type
- 18.6.5. Technology Platform
- 18.6.6. Drug Class
- 18.6.7. Route of Administration
- 18.6.8. Molecule Type
- 18.6.9. Patient Demographics
- 18.6.10. End-Users
- 18.7. South Korea Precision Oncology Therapies Market
- 18.7.1. Country Segmental Analysis
- 18.7.2. Therapy Type
- 18.7.3. Cancer Type
- 18.7.4. Biomarker Type
- 18.7.5. Technology Platform
- 18.7.6. Drug Class
- 18.7.7. Route of Administration
- 18.7.8. Molecule Type
- 18.7.9. Patient Demographics
- 18.7.10. End-Users
- 18.8. Australia and New Zealand Precision Oncology Therapies Market
- 18.8.1. Country Segmental Analysis
- 18.8.2. Therapy Type
- 18.8.3. Cancer Type
- 18.8.4. Biomarker Type
- 18.8.5. Technology Platform
- 18.8.6. Drug Class
- 18.8.7. Route of Administration
- 18.8.8. Molecule Type
- 18.8.9. Patient Demographics
- 18.8.10. End-Users
- 18.9. Indonesia Precision Oncology Therapies Market
- 18.9.1. Country Segmental Analysis
- 18.9.2. Therapy Type
- 18.9.3. Cancer Type
- 18.9.4. Biomarker Type
- 18.9.5. Technology Platform
- 18.9.6. Drug Class
- 18.9.7. Route of Administration
- 18.9.8. Molecule Type
- 18.9.9. Patient Demographics
- 18.9.10. End-Users
- 18.10. Malaysia Precision Oncology Therapies Market
- 18.10.1. Country Segmental Analysis
- 18.10.2. Therapy Type
- 18.10.3. Cancer Type
- 18.10.4. Biomarker Type
- 18.10.5. Technology Platform
- 18.10.6. Drug Class
- 18.10.7. Route of Administration
- 18.10.8. Molecule Type
- 18.10.9. Patient Demographics
- 18.10.10. End-Users
- 18.11. Thailand Precision Oncology Therapies Market
- 18.11.1. Country Segmental Analysis
- 18.11.2. Therapy Type
- 18.11.3. Cancer Type
- 18.11.4. Biomarker Type
- 18.11.5. Technology Platform
- 18.11.6. Drug Class
- 18.11.7. Route of Administration
- 18.11.8. Molecule Type
- 18.11.9. Patient Demographics
- 18.11.10. End-Users
- 18.12. Vietnam Precision Oncology Therapies Market
- 18.12.1. Country Segmental Analysis
- 18.12.2. Therapy Type
- 18.12.3. Cancer Type
- 18.12.4. Biomarker Type
- 18.12.5. Technology Platform
- 18.12.6. Drug Class
- 18.12.7. Route of Administration
- 18.12.8. Molecule Type
- 18.12.9. Patient Demographics
- 18.12.10. End-Users
- 18.13. Rest of Asia Pacific Precision Oncology Therapies Market
- 18.13.1. Country Segmental Analysis
- 18.13.2. Therapy Type
- 18.13.3. Cancer Type
- 18.13.4. Biomarker Type
- 18.13.5. Technology Platform
- 18.13.6. Drug Class
- 18.13.7. Route of Administration
- 18.13.8. Molecule Type
- 18.13.9. Patient Demographics
- 18.13.10. End-Users
- 19. Middle East Precision Oncology Therapies Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Middle East Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 19.3.1. Therapy Type
- 19.3.2. Cancer Type
- 19.3.3. Biomarker Type
- 19.3.4. Technology Platform
- 19.3.5. Drug Class
- 19.3.6. Route of Administration
- 19.3.7. Molecule Type
- 19.3.8. Patient Demographics
- 19.3.9. End-Users
- 19.3.10. Country
- 19.3.10.1. Turkey
- 19.3.10.2. UAE
- 19.3.10.3. Saudi Arabia
- 19.3.10.4. Israel
- 19.3.10.5. Rest of Middle East
- 19.4. Turkey Precision Oncology Therapies Market
- 19.4.1. Country Segmental Analysis
- 19.4.2. Therapy Type
- 19.4.3. Cancer Type
- 19.4.4. Biomarker Type
- 19.4.5. Technology Platform
- 19.4.6. Drug Class
- 19.4.7. Route of Administration
- 19.4.8. Molecule Type
- 19.4.9. Patient Demographics
- 19.4.10. End-Users
- 19.5. UAE Precision Oncology Therapies Market
- 19.5.1. Country Segmental Analysis
- 19.5.2. Therapy Type
- 19.5.3. Cancer Type
- 19.5.4. Biomarker Type
- 19.5.5. Technology Platform
- 19.5.6. Drug Class
- 19.5.7. Route of Administration
- 19.5.8. Molecule Type
- 19.5.9. Patient Demographics
- 19.5.10. End-Users
- 19.6. Saudi Arabia Precision Oncology Therapies Market
- 19.6.1. Country Segmental Analysis
- 19.6.2. Therapy Type
- 19.6.3. Cancer Type
- 19.6.4. Biomarker Type
- 19.6.5. Technology Platform
- 19.6.6. Drug Class
- 19.6.7. Route of Administration
- 19.6.8. Molecule Type
- 19.6.9. Patient Demographics
- 19.6.10. End-Users
- 19.7. Israel Precision Oncology Therapies Market
- 19.7.1. Country Segmental Analysis
- 19.7.2. Therapy Type
- 19.7.3. Cancer Type
- 19.7.4. Biomarker Type
- 19.7.5. Technology Platform
- 19.7.6. Drug Class
- 19.7.7. Route of Administration
- 19.7.8. Molecule Type
- 19.7.9. Patient Demographics
- 19.7.10. End-Users
- 19.8. Rest of Middle East Precision Oncology Therapies Market
- 19.8.1. Country Segmental Analysis
- 19.8.2. Therapy Type
- 19.8.3. Cancer Type
- 19.8.4. Biomarker Type
- 19.8.5. Technology Platform
- 19.8.6. Drug Class
- 19.8.7. Route of Administration
- 19.8.8. Molecule Type
- 19.8.9. Patient Demographics
- 19.8.10. End-Users
- 20. Africa Precision Oncology Therapies Market Analysis
- 20.1. Key Segment Analysis
- 20.2. Regional Snapshot
- 20.3. Africa Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 20.3.1. Therapy Type
- 20.3.2. Cancer Type
- 20.3.3. Biomarker Type
- 20.3.4. Technology Platform
- 20.3.5. Drug Class
- 20.3.6. Route of Administration
- 20.3.7. Molecule Type
- 20.3.8. Patient Demographics
- 20.3.9. End-Users
- 20.3.10. Country
- 20.3.10.1. South Africa
- 20.3.10.2. Egypt
- 20.3.10.3. Nigeria
- 20.3.10.4. Algeria
- 20.3.10.5. Rest of Africa
- 20.4. South Africa Precision Oncology Therapies Market
- 20.4.1. Country Segmental Analysis
- 20.4.2. Therapy Type
- 20.4.3. Cancer Type
- 20.4.4. Biomarker Type
- 20.4.5. Technology Platform
- 20.4.6. Drug Class
- 20.4.7. Route of Administration
- 20.4.8. Molecule Type
- 20.4.9. Patient Demographics
- 20.4.10. End-Users
- 20.5. Egypt Precision Oncology Therapies Market
- 20.5.1. Country Segmental Analysis
- 20.5.2. Therapy Type
- 20.5.3. Cancer Type
- 20.5.4. Biomarker Type
- 20.5.5. Technology Platform
- 20.5.6. Drug Class
- 20.5.7. Route of Administration
- 20.5.8. Molecule Type
- 20.5.9. Patient Demographics
- 20.5.10. End-Users
- 20.6. Nigeria Precision Oncology Therapies Market
- 20.6.1. Country Segmental Analysis
- 20.6.2. Therapy Type
- 20.6.3. Cancer Type
- 20.6.4. Biomarker Type
- 20.6.5. Technology Platform
- 20.6.6. Drug Class
- 20.6.7. Route of Administration
- 20.6.8. Molecule Type
- 20.6.9. Patient Demographics
- 20.6.10. End-Users
- 20.7. Algeria Precision Oncology Therapies Market
- 20.7.1. Country Segmental Analysis
- 20.7.2. Therapy Type
- 20.7.3. Cancer Type
- 20.7.4. Biomarker Type
- 20.7.5. Technology Platform
- 20.7.6. Drug Class
- 20.7.7. Route of Administration
- 20.7.8. Molecule Type
- 20.7.9. Patient Demographics
- 20.7.10. End-Users
- 20.8. Rest of Africa Precision Oncology Therapies Market
- 20.8.1. Country Segmental Analysis
- 20.8.2. Therapy Type
- 20.8.3. Cancer Type
- 20.8.4. Biomarker Type
- 20.8.5. Technology Platform
- 20.8.6. Drug Class
- 20.8.7. Route of Administration
- 20.8.8. Molecule Type
- 20.8.9. Patient Demographics
- 20.8.10. End-Users
- 21. South America Precision Oncology Therapies Market Analysis
- 21.1. Key Segment Analysis
- 21.2. Regional Snapshot
- 21.3. South America Precision Oncology Therapies Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 21.3.1. Therapy Type
- 21.3.2. Cancer Type
- 21.3.3. Biomarker Type
- 21.3.4. Technology Platform
- 21.3.5. Drug Class
- 21.3.6. Route of Administration
- 21.3.7. Molecule Type
- 21.3.8. Patient Demographics
- 21.3.9. End-Users
- 21.3.10. Country
- 21.3.10.1. Brazil
- 21.3.10.2. Argentina
- 21.3.10.3. Rest of South America
- 21.4. Brazil Precision Oncology Therapies Market
- 21.4.1. Country Segmental Analysis
- 21.4.2. Therapy Type
- 21.4.3. Cancer Type
- 21.4.4. Biomarker Type
- 21.4.5. Technology Platform
- 21.4.6. Drug Class
- 21.4.7. Route of Administration
- 21.4.8. Molecule Type
- 21.4.9. Patient Demographics
- 21.4.10. End-Users
- 21.5. Argentina Precision Oncology Therapies Market
- 21.5.1. Country Segmental Analysis
- 21.5.2. Therapy Type
- 21.5.3. Cancer Type
- 21.5.4. Biomarker Type
- 21.5.5. Technology Platform
- 21.5.6. Drug Class
- 21.5.7. Route of Administration
- 21.5.8. Molecule Type
- 21.5.9. Patient Demographics
- 21.5.10. End-Users
- 21.6. Rest of South America Precision Oncology Therapies Market
- 21.6.1. Country Segmental Analysis
- 21.6.2. Therapy Type
- 21.6.3. Cancer Type
- 21.6.4. Biomarker Type
- 21.6.5. Technology Platform
- 21.6.6. Drug Class
- 21.6.7. Route of Administration
- 21.6.8. Molecule Type
- 21.6.9. Patient Demographics
- 21.6.10. End-Users
- 22. Key Players/ Company Profile
- 22.1. AbbVie Inc.
- 22.1.1. Company Details/ Overview
- 22.1.2. Company Financials
- 22.1.3. Key Customers and Competitors
- 22.1.4. Business/ Industry Portfolio
- 22.1.5. Product Portfolio/ Specification Details
- 22.1.6. Pricing Data
- 22.1.7. Strategic Overview
- 22.1.8. Recent Developments
- 22.2. Amgen Inc.
- 22.3. Astellas Pharma Inc.
- 22.4. AstraZeneca PLC
- 22.5. Bayer AG
- 22.6. Bristol-Myers Squibb Company
- 22.7. Daiichi Sankyo Company, Limited
- 22.8. Eisai Co., Ltd.
- 22.9. Eli Lilly and Company
- 22.10. Exact Sciences Corporation
- 22.11. Gilead Sciences, Inc.
- 22.12. GlaxoSmithKline plc
- 22.13. Incyte Corporation
- 22.14. Johnson & Johnson
- 22.15. Merck & Co., Inc.
- 22.16. Novartis AG
- 22.17. Pfizer Inc.
- 22.18. Regeneron Pharmaceuticals, Inc.
- 22.19. Roche Holdings AG
- 22.20. Sanofi S.A.
- 22.21. Seagen Inc.
- 22.22. Takeda Pharmaceutical Company Limited
- 22.23. Other Key Players
- 22.1. AbbVie Inc.
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
Our research design integrates both demand-side and supply-side analysis through a balanced combination of primary and secondary research methodologies. By utilizing both bottom-up and top-down approaches alongside rigorous data triangulation methods, we deliver robust market intelligence that supports strategic decision-making.
MarketGenics' comprehensive research design framework ensures the delivery of accurate, reliable, and actionable market intelligence. Through the integration of multiple research approaches, rigorous validation processes, and expert analysis, we provide our clients with the insights needed to make informed strategic decisions and capitalize on market opportunities.
MarketGenics leverages a dedicated industry panel of experts and a comprehensive suite of paid databases to effectively collect, consolidate, and analyze market intelligence.
Our approach has consistently proven to be reliable and effective in generating accurate market insights, identifying key industry trends, and uncovering emerging business opportunities.
Through both primary and secondary research, we capture and analyze critical company-level data such as manufacturing footprints, including technical centers, R&D facilities, sales offices, and headquarters.
Our expert panel further enhances our ability to estimate market size for specific brands based on validated field-level intelligence.
Our data mining techniques incorporate both parametric and non-parametric methods, allowing for structured data collection, sorting, processing, and cleaning.
Demand projections are derived from large-scale data sets analyzed through proprietary algorithms, culminating in robust and reliable market sizing.
The bottom-up approach builds market estimates by starting with the smallest addressable market units and systematically aggregating them to create comprehensive market size projections.
This method begins with specific, granular data points and builds upward to create the complete market landscape.
Customer Analysis → Segmental Analysis → Geographical Analysis
The top-down approach starts with the broadest possible market data and systematically narrows it down through a series of filters and assumptions to arrive at specific market segments or opportunities.
This method begins with the big picture and works downward to increasingly specific market slices.
TAM → SAM → SOM
While analysing the market, we extensively study secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and commercial report. Secondary sources that we utilize are not only the public sources, but it is combination of Open Source, Associations, Paid Databases, MG Repository & Knowledgebase and Others.
- Company websites, annual reports, financial reports, broker reports, and investor presentations
- National government documents, statistical databases and reports
- News articles, press releases and web-casts specific to the companies operating in the market, Magazines, reports, and others
- We gather information from commercial data sources for deriving company specific data such as segmental revenue, share for geography, product revenue, and others
- Internal and external proprietary databases (industry-specific), relevant patent, and regulatory databases
- Governing Bodies, Government Organizations
- Relevant Authorities, Country-specific Associations for Industries
We also employ the model mapping approach to estimate the product level market data through the players product portfolio
Primary research/ interviews is vital in analyzing the market. Most of the cases involves paid primary interviews. Primary sources includes primary interviews through e-mail interactions, telephonic interviews, surveys as well as face-to-face interviews with the different stakeholders across the value chain including several industry experts.
| Type of Respondents | Number of Primaries |
|---|---|
| Tier 2/3 Suppliers | ~20 |
| Tier 1 Suppliers | ~25 |
| End-users | ~25 |
| Industry Expert/ Panel/ Consultant | ~30 |
| Total | ~100 |
MG Knowledgebase
• Repository of industry blog, newsletter and case studies
• Online platform covering detailed market reports, and company profiles
- Historical Trends – Past market patterns, cycles, and major events that shaped how markets behave over time. Understanding past trends helps predict future behavior.
- Industry Factors – Specific characteristics of the industry like structure, regulations, and innovation cycles that affect market dynamics.
- Macroeconomic Factors – Economic conditions like GDP growth, inflation, and employment rates that affect how much money people have to spend.
- Demographic Factors – Population characteristics like age, income, and location that determine who can buy your product.
- Technology Factors – How quickly people adopt new technology and how much technology infrastructure exists.
- Regulatory Factors – Government rules, laws, and policies that can help or restrict market growth.
- Competitive Factors – Analyzing competition structure such as degree of competition and bargaining power of buyers and suppliers.
Multiple Regression Analysis
- Identify and quantify factors that drive market changes
- Statistical modeling to establish relationships between market drivers and outcomes
Time Series Analysis – Seasonal Patterns
- Understand regular cyclical patterns in market demand
- Advanced statistical techniques to separate trend, seasonal, and irregular components
Time Series Analysis – Trend Analysis
- Identify underlying market growth patterns and momentum
- Statistical analysis of historical data to project future trends
Expert Opinion – Expert Interviews
- Gather deep industry insights and contextual understanding
- In-depth interviews with key industry stakeholders
Multi-Scenario Development
- Prepare for uncertainty by modeling different possible futures
- Creating optimistic, pessimistic, and most likely scenarios
Time Series Analysis – Moving Averages
- Sophisticated forecasting for complex time series data
- Auto-regressive integrated moving average models with seasonal components
Econometric Models
- Apply economic theory to market forecasting
- Sophisticated economic models that account for market interactions
Expert Opinion – Delphi Method
- Harness collective wisdom of industry experts
- Structured, multi-round expert consultation process
Monte Carlo Simulation
- Quantify uncertainty and probability distributions
- Thousands of simulations with varying input parameters
Our research framework is built upon the fundamental principle of validating market intelligence from both demand and supply perspectives. This dual-sided approach ensures comprehensive market understanding and reduces the risk of single-source bias.
Demand-Side Analysis: We understand end-user/application behavior, preferences, and market needs along with the penetration of the product for specific application.
Supply-Side Analysis: We estimate overall market revenue, analyze the segmental share along with industry capacity, competitive landscape, and market structure.
Data triangulation is a validation technique that uses multiple methods, sources, or perspectives to examine the same research question, thereby increasing the credibility and reliability of research findings. In market research, triangulation serves as a quality assurance mechanism that helps identify and minimize bias, validate assumptions, and ensure accuracy in market estimates.
- Data Source Triangulation – Using multiple data sources to examine the same phenomenon
- Methodological Triangulation – Using multiple research methods to study the same research question
- Investigator Triangulation – Using multiple researchers or analysts to examine the same data
- Theoretical Triangulation – Using multiple theoretical perspectives to interpret the same data
